Interdisciplinary GU Cancer Forum 2025 Combination Therapies in prostate cancer, active surveillance, GG1 prostate cancer, radical prostatectomy.

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer oral abstract session and a presentation by Dr. Theodore DeWeese discussing a phase 3, randomized, placebo-controlled clinical ...

Interdisciplinary GU Cancer Forum 2025, prostate cancer, de novo high-volume metastatic hormone-sensitive prostate cancer (mHSPC), Advances in Immunotherapy for prostate cancer, 177Lu-PSMA radioligand ...

Interdisciplinary GU Cancer Forum 2025 Prostate Cancer, Artificial Intelligence in Molecular Targeted Imaging, ChatGPT by OpenAI, aPROMISE platform.

Interdisciplinary GU Cancer Forum 2025, Prostate Cancer, Neoadjuvant Management of High-Risk Prostate Cancer, PROTEUS trial, GUNS trial, Genomic Umbrella Neoadjuvant Study, apalutamide, FOXA1 ...

Interdisciplinary GU Cancer Forum 2025, Emerging Data and Advances in Prostate cancer Screening, Prostate cancer, homologous recombination repair (HRR), metastatic castration-resistant prostate cancer ...

Zachary Klaassen speaks with Adrien Holzgreve about the FLEX-MRT trial, which aims to personalize lutetium-177 PSMA radioligand therapy delivery. Currently, Pluvicto™ follows fixed dosing from the ...

James Wysock joins Zachary Klaassen to discuss improving prostate cancer diagnostics through better biopsy needle technology. Dr. Wysock highlights early experience with the SUREcore® Biopsy Needle ...

SNMMI 2025 novel PSMA-targeting drug 177Lu-P17-088, metastatic castration-resistant prostate cancer (mCRPC), VISION and PSMAfore trials, PCWG3 guidelines.

Peter Clark presented results from the SunRISe-1 study at SESAUA 2025, evaluating TAR-200, an intravesical sustained-release gemcitabine system, in BCG-unresponsive high-risk non-muscle invasive ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

AUA 2024, Non–muscle-Invasive Bladder Cancer (NMIBC), TAR-210, erdafitinib, MoonRISe-1 study, FGFR Alterations, tyrosine kinase inhibitor, gemcitabine.